The effectiveness of Novartis' (NVS) immune-system drug Certican was confirmed in the largest...

|About: Novartis AG (NVS)|By:, SA News Editor

The effectiveness of Novartis' (NVS) immune-system drug Certican was confirmed in the largest trial to date of liver-transplant patients, with the treatment also able to improve renal function in the two-year Phase III study. Certican is approved in the EU for liver transplant patients, with an FDA approval decision expected at the end of the year. (PR)